|Mr. Alan Thomas Hirzel BS, MS, MBA||CEO & Exec. Director||1.12M||N/A||49|
|Mr. Gavin Hilary James Wood BA (Hons), ACA||CFO & Exec. Director||569k||N/A||47|
|Mr. Mark Bushfield Ph.D.||Scientific Director||N/A||N/A||N/A|
|Mr. Sean Hickey BSc||Chief Information Officer||N/A||N/A||N/A|
|Ms. Suzanne E. Smith LLB (Hons), MBA||Chief Legal Officer & Company Sec.||N/A||N/A||N/A|
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies, biochemicals, isotype controls, flow cytometry multi-color selectors, kits, loading controls, lysates, peptides, proteins, slides, tags and cell markers, and tools and reagents. Its products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics and nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells, as well as in drug discovery products and services. Abcam plc also engages in sales and distribution, and financing and investing activities, as well as sells its products online. It offers validated antibodies and other binders, and assays to the research and clinical communities to help advance the understanding of biology and causes of disease. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.
Abcam Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.